Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Argent Biopharma ( (AU:RGT) ).
Argent BioPharma has successfully completed a US$4,500,000 capital raise by issuing 11,250,000 ordinary shares at US$0.40 per share, significantly above recent market prices. This funding will advance its drug development pipeline, with a focus on CannEpil® and its clinical studies, and supports strategic operational reviews for long-term sustainability, including plans for a US national listing.
More about Argent Biopharma
Argent BioPharma Limited is a clinical-stage biopharmaceutical company specializing in neuroimmunology. It focuses on developing advanced nano-medicines to address unmet medical needs in central nervous system disorders and immune-related conditions. The company utilizes cutting-edge technologies, including the Neuro-Immune Modulatory System, to create a robust pipeline targeting complex diseases such as chronic, inflammatory, and neurodegenerative conditions. Its lead candidates include CannEpil®, CogniCann®, and CimetrA®.
YTD Price Performance: 0%
Average Trading Volume: 6,300
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.75M
See more insights into RGT stock on TipRanks’ Stock Analysis page.
